Enzalutamide shows overall survival benefits
Enzalutamide has previously been shown to significantly improve metastasis-free survival in men with nonmetastatic, castration-resistant prostate cancer and rapidly increasing PSA levels while taking androgen-deprivation therapy (ADT). Final results from the PROSPER trial show that overall survival is also increased.
The final analysis shows that the addition of enzalutamide (160mg once daily) to ADT was associated with median overall survival of 67 months compared to 56 months with placebo plus ADT (hazard ratio 0.73; 95% CI 0.61–0.89; p=0.001).
The rate of adverse events of grade 3 or higher was 17 per 100 patient-years in the enzalutamide group and 20 per 100 patient-years in the placebo group. The most frequently reported events in the enzalutamide group were fatigue and musculoskeletal events.